Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Save

Date Added
September 26th, 2017
PRO Number
Pro00069122
Researcher
John Sturdivant

Silhouette
Keywords
Cardiovascular
Summary

The purpose of this research study is to evaluate the different ways to program a Cardiac Resynchronization Therapy Defibrillator (CRT-D) through the use of software built into the CRT-D system. A CRT-D does not cure heart failure, but many people who receive a CRT device notice that they feel better. The objective of the device programming required by the SMART CRT study is to provide heart failure therapy which improves heart function.

Institution
MUSC
Recruitment Contact
Deborah Everidge
843-792-2944
adamsde@musc.edu

AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial Save

Date Added
November 22nd, 2016
PRO Number
Pro00060406
Researcher
John Sturdivant

Silhouette
Keywords
Cardiovascular, Heart
Summary

The purpose of the AMPLATZER Amulet Left Atrial Appendage (LAA) Occluder Trial is to find out if the Amulet device is safe and effective when compared to another LAA closure device made by another medical device company named Boston Scientific. The other device, called the WATCHMAN LAA closure device, is approved for use in the United States and many countries in Europe, Australia, and other nations. It is implanted in some patients with non-valvular atrial fibrillation to reduce the risk of stroke. The WATCHMAN device will be used as the Control device in this study.

Institution
MUSC
Recruitment Contact
Deborah Everidge
843-792-2944
adamsde@musc.edu

Understanding Outcomes with the EMBLEM™ S-ICD in Primary Prevention Patients with Low Ejection Fraction Save

Date Added
September 20th, 2016
PRO Number
Pro00057463
Researcher
John Sturdivant

Silhouette
Keywords
Cardiovascular, Heart
Summary

The primary objective is to assess the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) programmed with zone cutoffs at 200 bpm and 250 bpm. The UNTOUCHED study will test this programming scheme designed to minimize inappropriate and unnecessary shocks in patients who have an indication for primary prevention of sudden cardiac death and low ejection fraction. Subjects will be followed semi-annually according to standard of care for a minimum of 18 months post implant.

Institution
MUSC
Recruitment Contact
Deborah Everidge
843-792-2944
adamsde@musc.edu

aMAZE TRIAL: Left Atrial Appendage Ligation with the LARIAT+ Suture Delivery System as Adjunctive Therapy to Pulmonary Vein Isolation (PVI) for Persistent or Longstanding Persistent Atrial Fibrillation Save

Date Added
October 27th, 2015
PRO Number
Pro00046852
Researcher
John Sturdivant

Silhouette
Keywords
Cardiovascular, Heart
Summary

The study is testing the safety and effectiveness of the LARIAT device in addition to a radiofrequency ablation in patients who have atrial fibrillation longer than 7 days but less than 3 years.

Institution
MUSC
Recruitment Contact
Deborah Everidge
843-792-2944
adamsde@musc.edu

Change_preferences

-- OR --

Create_login